Lorin Thompson

Affiliations: 
1997 Bristol Myers Squibb 
Google:
"Lorin Thompson"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Mellion ML, Ronco L, Berends CL, et al. (2021) Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Dystrophy (FSHD): Safety, Tolerability, Pharmacokinetics, and Target Engagement. British Journal of Clinical Pharmacology
Zhang Y, Boy KM, Wu YJ, et al. (2020) Synthesis of Functionalized Derivatives of the Gamma-Secretase Modulator BMS-932481 and Identification of its Major Metabolite. Bioorganic & Medicinal Chemistry Letters. 127530
Rojas LA, Valentine E, Accorsi A, et al. (2020) P38α Regulates Expression of DUX4 in Facioscapulohumeral Muscular Dystrophy. The Journal of Pharmacology and Experimental Therapeutics
Boy KM, Guernon JM, Zuev DS, et al. (2019) Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481. Acs Medicinal Chemistry Letters. 10: 312-317
Luo G, Chen L, Easton A, et al. (2019) Correction to Discovery of Indole- and Indazole-acylsulfonamides as Potent and Selective Na1.7 Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry
Wu YJ, Venables B, Guernon J, et al. (2018) Discovery of new indole-based acylsulfonamide Na1.7 inhibitors. Bioorganic & Medicinal Chemistry Letters
Luo G, Chen L, Easton A, et al. (2018) Discovery of Indole- and Indazole-Acylsulfonamides as Potent and Selective NaV1.7 Inhibitors for the Treatment of Pain. Journal of Medicinal Chemistry
Marcin LR, Warrier J, Thangathirupathy S, et al. (2018) BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder. Acs Medicinal Chemistry Letters. 9: 472-477
Wu YJ, Guernon J, McClure A, et al. (2018) Discovery of morpholine-based aryl sulfonamides as Na1.7 inhibitors. Bioorganic & Medicinal Chemistry Letters
Bristow LJ, Gulia J, Weed MR, et al. (2017) Preclinical Characterization of (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate N-Methyl-D-Aspartate 2B (GluN2B) Receptor Negative Allosteric Modulator with Potential in Major Depressive Disorder. The Journal of Pharmacology and Experimental Therapeutics
See more...